QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SC who wrote (296)	3/19/1998 11:37:00 AM
From: Ian@SI	of 1321

SC, Today's status quo is that 50% of people over age 50 will ultimately go blind. The QLT promise is that AMD can be arrested prior to debilitating vision loss. Adding a $1B market annually in the developed countries should be quite lucrative for QLT while they're the only game in town. Yes, the treatments would be required about 4 times annually for the rest of the patient's life. As I understood the article, the Phase IIIb trial was extending the scope to earlier onset of the disease. I believe the article indicated that they started with more advanced cases in case there were unwanted side effects from long term usage of the treatment. I'm not an expert on getting FDA approval. QLT is. They've already received approvals from regulators globally for the use of this family of drugs for various forms of cancer. ... which is another nice thing about the company. Rather than diluting our holdings to complete R&D and approvals, they do have a good source of income from sales. Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next